CALL US:022-2204 0015 / 16 / 17
Shardul Nautiyal, Mumbai September 30 , 2017
Gujarat has achieved the distinction of having the highest number of 280 WHO – GMP certified manufacturing units in the country followed by Maharashtra with 222 units, Himanchal Pradesh at 134, Telangana at 131 and Uttarakhand at 97.

West Bengal has the least number of 4 WHO-GMP certified manufacturing units with Sikkim being the only state in the North- Eastern region of the country having 16 WHO – GMP certified manufacturing units.

Accounting for nearly 40 per cent of India’s pharma production and 28 per cent of pharma exports, Gujarat has registered a growth of 445 per cent in pharma exports in the past one decade. Exports worth 3,060 million US Dollars has been achieved in 2016 from Gujarat in comparison to exports worth 562 million US Dollars in 2006.

Other Union Territories and states like Arunachal Pradesh, Andaman & Nicobar, Assam, Bihar, Chandigarh, Chhattisgarh, Jharkhand, Lakshadweep, Manipur, Meghalaya, Mizoram, Nagaland, Tripura and Odisha have no WHO-GMP certified manufacturing units.

The country today has a total of 1314 WHO -GMP certified manufacturing units. Besides this, Gujarat has 24 TGA certified, 15 EU certified and 16 PICS certified manufacturing units. It boasts of 158 formulation units and 97 bulk drug units. It has 40 per cent of CROs and 40 per cent of CRAMS companies.

Over 3300 manufacturing units are located across the state in four large clusters with 5 Special Economic Zones in an area of over 1500 hectares, as per official data.
The growth in pharma exports would also get a boost with setting up of a dedicated medical device testing lab for the first time in the country at Vadodara in Gujarat. A final proposal on the same has been sent to the Union health ministry for its implementation.

India today lacks in registering and thereby reporting adverse events due to faulty medical devices at the point of care. Gujarat is also coming up with a manufacturing park for medical devices at Sanand. Medical devices manufacturing requires certain high investment facilities which are too capital intensive for individual manufacturers to invest upon. A park with in-house high investment scientific facilities would help manufacturers reduce the cost of manufacturing by more than 40 per cent to 50 per cent.

Currently, due to lack of such centrally located common facilities, manufacturers do not undertake production of technologies and therefore send their products abroad for process up-gradation and value addition.

Share This Story

Leave a Reply
Your name (required)   Your email (required)
Website (required)
Enter Code (Required)





Food safety has already become the sole criteria of food quality all over the world, thanks to the fact that these days, ...


About Us
Contact Us
News Archives

Product Finder
Features and Articles
Chronicle Pharmabiz
Food & Bevergae News
Ingredients South Asia
Media Information
Rate Card
Copyright © 2013 Saffron Media Pvt Ltd. All Rights Reserved.
Best View in Internet Explorer(9.0) or Firefox(26.0)